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Feng Shen, MD, George A Poultsides, MD, FACS, Oliver Soubrane, MD, PhD, Guillaume Martel, MD, FACS,
B Groot Koerkamp, MD, PhD, Alfredo Guglielmi, MD, Endo Itaru, MD, PhD, Federico N Aucejo, MD,
Timothy M Pawlik, MD, MPH, PhD, FACSBACKGROUND: Accurate prediction of prognosis for patients with intrahepatic cholangiocarcinoma (ICC) remains a chal-
lenge. We sought to define a preoperative risk tool to predict long-term survival after resection of ICC.
STUDY DESIGN: Patients who underwent hepatectomy for ICC at 1 of 16 major hepatobiliary centers between 1990 and 2015
were identified. Clinicopathologic data were analyzed and a prognostic model was developed based on the
regression b-coefficients on data in training set. The model was subsequently assessed using a validation set.
RESULTS: Among 538 patients, most patients had a solitary tumor (median tumor number 1; interquartile range 1 to
2) and median tumor size was 5.7 cm (interquartile range 4.0 to 8.0 cm). Median and 5-year overall survival
was 39.0 months and 39.0%, respectively. On multivariable analyses, preoperative factors associated with
long-term survival included tumor size (hazard ratio [HR] 1.12; 95% CI 1.06 to 1.18), natural logarithm
carbohydrate antigen 19-9 level (HR 1.33; 95% CI 1.22 to 1.45), albumin level (HR 0.76; 95% CI 0.55 to
0.99), and neutrophil to lymphocyte ratio (HR 1.05; 95% CI 1.02 to 1.09). A weighted composite
prognostic score was constructed based on these factors: [9 þ (1.12  tumor size) þ (2.81  natural
logarithm carbohydrate antigen 19-9) þ (0.50  neutrophil to lymphocyte ratio) þ (2.79  albumin)].
The model demonstrated good performance in the testing (area under the curve 0.696) and validation
(0.691) datasets. The model performed better than both the T categories (area under the curve 0.532) and
the cumulative stage classifications in the American Joint Committee on Cancer staging manual, 8th edition
(area under the curve 0.559). When assessing risk of death within 1 year of operation, a risk score25 had a
positive predictive value of 59.8% compared with a positive predictive value of 35.3% for American Joint
Committee on Cancer staging manual, 8th edition T4 disease and 31.8% for stage IIIB disease.
CONCLUSIONS: Postsurgical long-term outcomes could be predicted using a composite weighted scoring system based
on preoperative clinical parameters. The preoperative risk model can be used to inform patient to
provider conversations and expectations before operation. (J Am Coll Surg 2018;226:393e403.
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AJCC ¼ American Joint Committee on Cancer
CA ¼ carbohydrate antigen
HR ¼ hazard ratio
ICC ¼ intrahepatic cholangiocarcinoma
IQR ¼ interquartile range
NLR ¼ neutrophil to lymphocyte ratio
OS ¼ overall survival
394 Sasaki et al Risk Score and Outcomes after Hepatectomy J Am Coll SurgAlthough resection is the cornerstone of treatment for
intrahepatic cholangiocarcinoma (ICC), outcomes after
operation are frequently poor.1-3 In fact, even among
carefully selected patients, median survival after operation
can be as low at 15 to 24 months and 5-year overall sur-
vival rates range from 20% to 40%.4-6 The high incidence
of recurrence after operation of ICC is difficult to explain.
Specifically, more than one-half of patients who undergo
curative intent resection of ICC experience recurrent dis-
ease within 2 years of operation.7 Of note, nonoperative
therapies, such as intra-arterial therapy and radiation ther-
apy, have been reported to have similar long-term
outcomes in some patients.8 For example, select patients
with inoperable ICC treated with intensity-modulated
radiotherapy had a reported median overall survival
(OS) of 30 months.9 In a separate study, patients with
advanced ICC treated with intra-arterial therapy had a
median survival of 13 to 15 months, with better outcomes
among patients who had a good radiologic response.10
Given the high risk of recurrence, as well as some reported
outcomes comparable with nonoperative therapy, better
preoperative patient selection of ICC patients is
necessary.2
Standardized preoperative risk assessment tools can
help to identify patients at the time of treatment selection
and thereby inform preoperative decisions around patient
management. To this end, staging systems and prognostic
models are currently used in many malignancies to
facilitate treatment decisions and provide guidance on
anticipated long-term outcomes.11,12 Prognostic models
that incorporate preoperative variables can be used to
help evaluate and plan treatment selection. Unfortunately,
the development and implementation of preoperative risk
scores have been somewhat limited. Specifically, while
several staging schemas and nomograms have been devel-
oped and validated for patients with resectable ICC, most
models to date have used variables that can only be
assessed postoperatively.13-17 A prognostic model that
allows for risk stratification at the time of treatment
selection among patients with surgically resectable ICC
has yet to be developed. As such, the objective of thecurrent study was to develop a preoperative risk score
for patients with surgically resectable ICC using an inter-
national, multi-institutional cohort of patients. Specif-
ically, using preoperative information on liver function,
morphology, and tumor biology, we sought to identify




From 1990 to 2015, patients who underwent curative-
intent liver resection for ICC at 16 major hepatobilliary
centers in the US, Europe, Asia, and Oceania (Cleveland
Clinic Foundation, Cleveland, Ohio; Johns Hopkins
University, Baltimore, Maryland; Emory University,
Atlanta, Georgia; Stanford University Medical Center,
Stanford, California; University of Virginia Health
System, Charlottesville, Virginia and Ottawa General
Hospital, Ottawa, Canada, Eastern Hepatobiliary Surgery
Hospital, Shanghai, China; Yokohama City University,
Yokohama, Japan; Royal Prince Alfred Hospital, Sydney,
Australia, Fundeni Clinical Institute, Bucharest,
Romania; Beaujon Hospital, Clichy, France; Curry
Cabral Hospital, Lisbon, Portugal; San Raffaele Hospital,
Milan, Italy; and Erasmus University Medical Centre
Rotterdam, Rotterdam, The Netherlands) were identified.
Patients who underwent macroscopically incomplete
resection (R2) or patients with concurrent extrahepatic
disease at the time of hepatectomy were excluded from
the study. The study was approved by the IRBs of the
respective institutions.
Preoperatively available data on liver function
(ie albumin), tumor morphology (ie tumor size on
imaging studies), tumor biology (ie preoperative carbo-
hydrate antigen (CA) 19-9 level), and systemic inflam-
matory response (ie neutrophil to lymphocyte ratio
[NLR]) were recorded. The primary end point of
the study was OS, which was defined as the time
from initial liver resection to the date of death or last
follow-up.
Statistical analysis
Summary statistics were reported as frequencies with
percentages or median values using interquartile ranges
(IQR). Differences between categorical values were
estimated using the chi-square test, and differences
between continuous values were assessed with the
Mann-Whitney U test or the Kruskal-Wallis test, as
appropriate. The normality assumption was violated in
the case of CA 19-9, as the distribution exhibited marked
right skewness. Therefore, natural logarithm











Serum total bilirubin, mg/dL, median (IQR) 0.7 (0.5e1.0)
Serum albumin level, g/dL, median (IQR) 4.2 (3.9e4.5)
Aspartate transaminase, IU/L, median (IQR) 29.0 (22.0e42.0)
Alanine transaminase, IU/L, median (IQR) 28.0 (18.0e44.0)
Neutrophil to lymphocyte ration, median
(IQR) 2.7 (2.0e4.1)
Serum carbohydrate antigen 19-9 level,




Maximum diameter of the tumor, cm,
median (IQR) 5.7 (4.0e8.0)
Pathology-proven satellite lesions, n (%)
Negative 437 (81.2)
Positive 101 (18.8)
Tumor morphology type (n ¼ 521),
n (%)
Mass-forming type 494 (94.8)
Non-mass-forming type 27 (5.2)




Vascular invasion, n (%)
Negative 381 (70.8)
Positive 157 (29.2)
Resection margin, n (%)
R0 493 (91.6)
R1 45 (8.4)
American Joint Committee on Cancer 8th ed









IQR, interquartile range; Nx, no pathologic lymph node status assessment.
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these variables on OS.
Before the analysis, the study cohort was randomly
internally divided into a test and a validation sub-
cohort. In the test sub-cohort, a number of possible pre-
operative predictors of survival (plus patient age) were
selected on the basis of clinical experience and assessed
through univariable analysis. Subsequently, a multivari-
able stepwise Cox regression analysis (backward elimina-
tion method) was performed to identify independent
predictors of decreased OS. The proportionality of haz-
ards assumption was confirmed using Schoenfeld’s global
test. Finally, the b-coefficients of the identified prognostic
factors were used to construct a weighted composite prog-
nostic score. The prognostic discrimination (the ability to
differentiate between low and high risk patients) of the
score was estimated with the aid of receiver operating
characteristic curve analysis and calculation of the area un-
der the curve, as described previously.18 Subsequently, the
prognostic discrimination of the score was internally vali-
dated in the validation sub-cohort. Analyses were per-
formed using SPSS software, version 24 (IBM Corp)
and STATA, version 13 (Stata Corp). A p value < 0.05
(2-tailed) was considered statistically significant.
RESULTS
Patient characteristics in the testing and validation
sub-cohorts
A total of 538 adult patients met eligibility criteria and
were included in the study population. Median follow-
up was 25.6 months (IQR 12.4 to 47.7 months). A total
of 283 patients died during the follow-up period and
median, 1-, 3-, and 5-year OS was 39.5 months,
81.5%, 52.6%, and 39.0%, respectively. Table 1 summa-
rizes the clinicopathologic characteristics of the study
cohort. The study population was randomly divided
into training and validation sub-cohorts, respectively.
Specifically, the training sub-cohort consisted of 269
patients with a median follow-up of 26.4 months (IQR
13.8 to 47.3 months); a total of 141 patients died during
the follow-up period and 1-, 3-, and 5-year OS was
82.1%, 55.0%, and 36.8%, respectively. The validation
sub-cohort consisted of 269 patients, with a median
follow-up of 25.3 months (IQR 11.4 to 47.8 months).
A total of 142 patients died during the follow-up period
and 1-, 3-, and 5-year OS was 80.9%, 50.3%, and
41.1%, respectively.
Table 2 summarizes the clinicopathologic characteris-
tics of the training and validation sub-cohorts. The
training and validation sub-cohorts were relatively
Table 2. Comparison of Patient Characteristics among Training vs Validation Datasets
Characteristic Training set (n ¼ 269) Validation set (n ¼ 269) p Value
Age, y, median (IQR) 58 (51e66) 57 (49e64) 0.739
Sex, n (%) 0.321
Male 180 (66.9) 168 (62.5)
Female 89 (33.1) 101 (37.5)
Region, n (%) 0.851
Western 80 (29.7) 83 (30.9)
Eastern 189 (70.3) 186 (69.1)
Serum total bilirubin, mg/dL, median (IQR) 0.7 (0.5e1.0) 0.7 (0.5e1.0) 0.908
Serum albumin level, g/dL, median (IQR) 4.2 (3.9e4.5) 4.2 (4.0e4.5) 0.924
Aspartate transaminase, IU/L, median (IQR) 30.3 (22.1e44.0) 28.0 (21.0e38.4) 0.026
Alanine transaminase, IU/L, median (IQR) 30.0 (18e44.9) 27.0 (18.0e41.0) 0.181
Neutrophil to lymphocyte ratio, median (IQR) 2.7 (2.1e4.1) 2.9 (2.0e4.1) 0.703
Serum carbohydrate antigen 19-9 levels, IU/mL, median (IQR) 42.6 (17.0e240.0) 48.6 (18.2e218.5) 0.379
No. of nodules, n (%) 0.677
Solitary 242 (90.0) 238 (88.5)
Multiple 27 (10.0) 31 (11.5)
Maximum diameter of the tumor, cm, median (IQR) 5.8 (4.0-8.0) 5.5 (3.6-8.0) 0.459
Pathology-proven satellite lesions, n (%) 0.008
Negative 206 (76.6) 231 (85.9)
Positive 63 (23.4) 38 (14.1)
Tumor morphology type (n ¼ 521), n (%) 1.000
Mass-forming type 247 (94.6) 247 (95.0)
Non-mass-forming type 14 (5.4) 13 (5.0)
Histologic differentiation (n ¼ 530), n (%) 0.601
Well/moderate 229 (86.4) 234 (88.3)
Poor 36 (13.6) 31 (11.7)
Vascular invasion, n (%) 1.000
Negative 191 (71.0) 190 (70.6)
Positive 78 (29.0) 79 (29.4)
Resection margin, n (%) 0.534
R0 244 (90.7) 249 (92.6)
R1 25 (9.3) 20 (7.4)
American Joint Committee on Cancer 8th T stage, n (%)
I 153 (53.2) 143 (53.2) 0.898
II 74 (29.4) 79 (29.4)
III 29 (14.5) 39 (14.5)
IV 13 (4.8) 8 (3)
Lymph node status, n (%) 0.021
Nx 104 (38.7) 81 (30.1)
N0 130 (48.3) 132 (49.1)
N1 35 (13.0) 56 (20.8)
IQR, interquartile range; Nx, no pathologic lymph node status assessment.
396 Sasaki et al Risk Score and Outcomes after Hepatectomy J Am Coll Surgwell balanced; in fact, only a small subset of variables
differed, including median aspartate transaminase levels
(30.3 IU/L: testing cohort vs 28.0 IU/L: validation
cohort; p ¼ 0.026), frequency of pathology-provensatellite lesions (23.4%: testing cohort vs 14.1%: valida-
tion cohort; p ¼ 0.008), and incidence of metastatic
lymph nodes (13.0%: testing cohort vs 20.8%: valida-
tion cohort; p ¼ 0.021).
Table 3. Factors Associated with Survival after Hepatectomy for Intrahepatic Cholangiocarcinoma
Factor p Value Coefficient SE Wald c2 Hazard ratio 95% CI
Training set
Serum albumin 0.047 0.279 0.150 3.8 0.76 0.55e0.99
NLR 0.009 0.050 0.018 7.2 1.05 1.02e1.09
LogN CA19-9 <0.001 0.281 0.041 43.7 1.33 1.22e1.45
Size (per cm) <0.001 0.112 0.026 18.6 1.12 1.06e1.18
Validation set
Serum albumin 0.026 0.328 0.148 4.9 0.72 0.54e0.96
NLR 0.008 0.046 0.017 7 1.05 1.01e1.08
LogN CA19-9 <0.001 0.263 0.040 42.3 1.30 1.20e1.41
Size (per cm) <0.001 0.103 0.025 15.8 1.11 1.06e1.17
CA 19-9, carbohydrate antigen 19-9; LogN, natural logarithm; NLR, neutrophil to lymphocyte ratio; Nx, no pathologic lymph node assessment.
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predictors of overall survival in the testing
sub-cohort
On stepwise Cox regression multivariable analyses of the
training dataset, preoperative factors associated with
long-term survival included albumin level (hazard ratio
[HR] 0.78; 95% CI 0.59 to 0.98), tumor size (HR
1.12; 95% CI 1.06 to 1.18), natural logarithm CA 19-9
level (HR 1.33; 95% CI 1.22 to 1.45), and neutrophil
to lymphocyte ratio (NLR) (HR 1.05; 95% CI 1.02 to
1.09) (Table 3). A risk score equation was constructed
based on the b-coefficients of these 4 independent prog-
nostic factors. The derivative scores in the training set
and validation set ranged from 9.0 to 53.0; for ease, a
fixed constant valued of 9 was added to weight the score
to avoid a negative score. In turn, the final weighted com-
posite prognostic model was: [9 þ (2.79  albumin) þ
(0.50  NLR) þ (2.81  natural logarithm CA 19-9) þ
(1.12  tumor size)]. Figure 1 demonstrates the distribu-
tion of the scores in the training, validation, and whole
cohort. Based on Harrel’s C-index, the discriminatory
performance in the training set was 0.696 (95% CIFigure 1. The distribution of the preoperative risk scores was nor-
mally distributed over the entire cohort with a median preoperative
risk score of 17.0.630 to 0.755); a comparable performance was observed
in the validation set (0.691; 95% CI 0.626 to 0.748).
Patients were then assigned to different score cate-
gories according to mortality risk: category 1 (score:
0 to 9), category 2 (score: 10 to 19), category 3 (score:
20 to 29), category 4 (score: 30 to 39), and category
5 (score: >40). Using the prognostic score, patients
with ICC could be incrementally stratified with regard
to median OS and 5-year OS (Fig. 2). Specifically,
category 1 patients had a median OS of not reached
and a 5-year OS of 66.1%; category 2 patients had a
median OS of 23.5 months and a 5-year OS of 19.2%;
category 3 patients had a median OS of 10.9 months
and a 5-year OS of 14.7%; and category 4 patients had
a median OS of 5.1 months and a 5-year OS of 0%
(p < 0.001). Notably, the preoperative risk score was
also associated with adverse postoperative pathologic fea-
tures (Table 4). Specifically, a higher preoperative risk
score was correlated with the presence of an increased
risk of adverse histopathologic features, such as satellite
lesions, vascular invasion, and poor tumor differentiation
(all p < 0.05).
Discriminatory ability of the proposed preoperative
score vs the American Joint Committee on Cancer,
8th edition, staging system
The performance of the scoring system was assessed rela-
tive to the 8th edition of the American Joint Committee
on Cancer (AJCC) T category designations, as well as
overall AJCC 8th edition stage (Fig. 3). Of note, the
prognostic discrimination ability of the preoperative
prognostic score (c-index 0.693; 95% CI 0.650 to
0.742) was better than the performance of the AJCC
8th edition T category designations (c-index 0.532;
95% CI 0.483 to 0.580) (p < 0.001) (Fig. 4). The
preoperative score also outperformed the overall
AJCC staging system. Specifically, Harrell’s C-index
Figure 2. (A) Using the preoperative prognostic score, patients
were categorized into different mortality risk group relative to long-
term overall survival. (B) Of note, a high preoperative risk score
was associated with a strong positive predictive value to predict the
chance of death within 15 months of operation. OS, overall survival.
398 Sasaki et al Risk Score and Outcomes after Hepatectomy J Am Coll Surgfor the preoperative score was 0.693 (95% CI 0.650 to
0.742) vs 0.559 (95% CI 0.498 to 0.619) for the full
AJCC staging system (both p < 0.001). Of note, in
assessing risk of death within 15 months after surgery
among patients in the entire cohort, a risk score 25
had a positive predictive value of 59.8% compared
with a positive predictive value of 35.3% for T4 disease
and 31.8% for stage IIIB disease according to the AJCC,
8th edition. Interestingly, patients with a preoperative
score >30 had an extremely adverse prognosis with a
positive predictive value of death within 15 months after
surgery of 64.9% (Fig. 2B).
DISCUSSION
To date, many prognostic schemesdincluding the most
commonly used AJCC staging systemdlargely have
focused on factors obtained postoperatively on patho-
logic assessment of the specimen. Although risk stratifica-
tion and prediction of prognosis after resection are
important, more data are needed to assess long-term
risk of death before operation. Preoperative assessment
of long-term survival benefit is particularly important
for surgical procedures potentially associated with majormorbidity, as well as those diseases that generally have a
poor prognosis. To this point, resection of ICC often ne-
cessitates a major hepatic resection and can be associated
with a higher risk of postoperative morbidity than liver
procedures for other indications (eg liver metastasis).19
In addition, ICC is an aggressive tumor that can often
be associated with a poor prognosis, even among patients
undergoing resection with curative intent.20 As such, bet-
ter preoperative prognostic stratification of patients with
ICC can help direct clinical decision making, as well as
provide information to help counsel patients. The cur-
rent study was important because by using a large inter-
national multi-institutional cohort of patients with ICC,
4 preoperative factors were identified that were strongly
associated with postoperative OS. Specifically, albumin
level, tumor size, CA 19-9 level, and NLR were each
correlated with long-term prognosis. Using these factors,
a novel preoperative score was developed and validated
that was able to stratify long-term survival after opera-
tion. Of note, the preoperative score had good discrimi-
natory ability on both the testing and validation cohorts.
In addition, the preoperative score had a number of sig-
nificant advantages over previous prognostic models.
First, it is, to our knowledge, among the only prognostic
scores to date that can be used preoperatively among pa-
tients with surgically resectable ICC.11,12 In turn, the
preoperative model allows for risk stratification at the
time of treatment selection, facilitating treatment deci-
sions (eg preoperative chemotherapy, nonoperative ICC
treatment modalities).21 In addition, the score might
enable surgeons to offer patients a more accurate prog-
nostic “forecast” at the time of the initial preoperative
consultation.22
Of note, the preoperative score outperformed the 8th
edition of the AJCC staging system, even though the
AJCC staging scheme mostly relies on postoperative path-
ologic data.23 The better performance of the preoperative
model was likely attributable to several factors. In partic-
ular, the current model had the advantage of using a
continuous risk score for patients with ICC. The fact
that we used a continuous, rather than categorical, model
could help explain the prognostic power of the model, as
data from other malignancies have noted that that the
accuracy of continuous risk scores is consistently superior
vs comparable models that use designated cutoff values.24
In particular, the use of binary variables to classify vari-
ables into categorical groupings can lead to loss of prog-
nostic power.24 In addition to how the data were
analyzed, the score incorporated a variety of prognostic
determinants that accounted for a wide range of factors,
including functional liver status, tumor morphology, tu-
mor biology, and host-tumor interactionsdall of which




Median (IQR) p Value
Pathology-proven satellite lesions 0.001
Negative 16.7 (11.6e222.4)
Positive 18.9 (14.5e24.8)
Tumor morphology type 0.165
Mass-forming type 17.1 (12.1e22.5)





















IQR, interquartile range; Nx, no pathologic lymph node status assessment.
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nosis of ICC.4
The preoperative score incorporated information on
host-tumor interaction through the inclusion of NLR,
which is a readily available marker of systemic inflamma-
tion.25 Importantly, chronic inflammation induced by
hepatitis, steatosis, liver flukes, hepatolithiasis, or primary
sclerosing cholangitis can be associated with an increased
risk of ICC development.26 In turn, the extent of the in-
flammatory response can impact long-term outcomes.27,28
More specifically, an elevated NLR can be indicative of
neutrophilia, lymphopenia, or a combination of both.
Neutrophilia can induce a favorable tumor microenviron-
ment by secreting molecules, such as vascular endothelial
growth factor, matrix metallopeptidase 9, and reactive
oxygen species, that degrade the extracellular matrix, pro-
moting angiogenesis, tumor growth, and metastasis.29,30
On the other hand, the presence of lymphopenia might
signify lower counts of tumor-specific CD8þ cytotoxic
T cells and, consequently, reduce the capacity to combattumor cells through immune surveillance.31-33 Although
NLR is a relatively simple proxy of host-tumor interac-
tions, its availability, ease of use, and robust association
with outcomes suggested that it could be a useful risk
score component.
Given the important role of chronic inflammation in the
pathophysiology of ICC, factors that counter-balance the
harmful effects of inflammation and oxidative stress can
result in improved outcomes. Specifically, albumin is
known to play a major role in the neutralization of reactive
oxygen and nitrogen species that, in turn, can cause DNA
damage and promote carcinogenesis.34-36 Importantly, low
albumin or albumin-based markers have been associated
with worse survival for several other malignancies. In
particular, in the case of primary liver tumors, albumin
has been demonstrated to suppress directly the prolifera-
tion of HCC cell line, thereby suggesting that albumin
might have an antiproliferative effect.37 In addition, as a
proxy of liver function, albumin levels have been associated
with outcomes, with increased albumin levels indicating
conserved liver function and a reduced risk of death.38
In addition to accounting for host-tumor interplay and
liver functional status, the preoperative score also incorpo-
rated an established marker of tumor biologydCA 19-9.
Preoperative CA 19-9 was been reported to be an inde-
pendent predictor of OS in several studies from Asia
and North America. Specifically, Ohtsuka and
colleagues39 reported on the prognostic impact of CA
19-9 for patients with resected ICC; in a separate study,
Wang and colleagues40 similarly noted the prognostic
impact of CA 19-9 and incorporated this preoperative
laboratory value into a prognostic nomogram, which
largely otherwise consisted of postoperative factors. Inter-
estingly, the authors noted that the discriminatory ability
of the nomogram was mainly attributable to the prog-
nostic power of CA 19-9, as the nomogram was otherwise
similar to previous staging systems and prognostic
models.40 The CA 19-9 cutoff levels have been difficult
to determine, however, and various cutoff values ranging
from 37 to 100 IU/mL have been used.41 The current
study avoided this problem by incorporating CA 19-9
values into the preoperative prognostic score as a contin-
uous variable, thereby avoiding the sacrifice of prognostic
information associated with reliance on categorical classi-
fications of such data.
Tumor size was also incorporated into the preoperative
prognostic score. Interestingly, the importance of tumor
size in ICC has been controversial. Although tumor size
was not incorporated into the 7th edition of the AJCC
staging system,42 a subsequent, adequately powered
meta-analysis reported that large tumor size was indeed
associated with worse long-term outcomes.33 Specifically,
Figure 3. The performance of the scoring system was assessed relative to the (A) 8th edition of the American
Joint Committee on Cancer (AJCC) T category designations and (B) overall final AJCC stage. Although the
preoperative risk model stratified overall survival in an incremental fashion, there was poor separation of
survival curves according to the T categories as patients with T2, T3, and T4 disease had overlapping survival.
In addition, the preoperative risk model similarly had an improved ability to stratify survival compared with
overall AJCC staging, which performed poorly.
400 Sasaki et al Risk Score and Outcomes after Hepatectomy J Am Coll SurgMavros and colleagues43 reported that the risk of worse
OS increased incrementally with each 1-cm increase in tu-
mor diameter. In the current study, when analyzed as a
continuous variable, we similarly noted that tumor size
had a prognostic impact on outcomes. Although several
previous studies failed to demonstrate an association of
tumor size with prognosis, the relatively small number
of patients with tumors smaller than the AJCC suggested
a 5-cm cutoff value might have limited the statistical
analyses.10 In the current study, 198 patients had an
ICC tumor <5 cm in diameter, suggesting the data
were less skewed in terms of tumor size than previous
studies. The use of both preoperative and postoperative
variables in the predictive models might have also negatedthe prognostic power of tumor size in previous studies.
For example, tumor size can exhibit strong collinearity
with histologic tumor grade, which is another important
postoperative determinant of prognosis.44 As the current
study did not include postoperative variables, the relative
prognostic power of tumor size might have been enhanced
by its capacity to serve as a proxy for the presence of the
aforementioned histopathologic features. To this end, a
higher preoperative risk score was correlated with the
presence of an increased risk of adverse histopathologic
features, such as vascular invasion and poor tumor
differentiation.
There has not been a randomized trial comparing the
efficacy of surgery vs nonoperative treatments, such as
Figure 4. In assessing overall prognostic discrimination in the validation subset, (A) the intrahepatic cholangiocarcinoma risk score
performed significantly better than the American Joint Committee on Cancer (AJCC) T categories. (B) The preoperative score risk also
outperformed final AJCC overall staging based on final pathology.
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of patients are often heterogeneous and difficult to
compare, the data suggest that a subgroup of patients
with aggressive disease derive minimal benefit from surgery
and may be managed with nonoperative approaches.8-10 In
fact, some patients with inoperable ICC treated with either
intra-arterial therapy or intensity-modulated radiotherapy
have had reported outcomes that were not too dissimilar
to the results of some patients treated with surgery.9,10 In
turn, these data suggest that a subset of patients with tech-
nically operable disease might not derive an incremental
benefit from resection compared with other nonoperative
modalities. To this point, the proposed score was designed
using disease-related factors that could be identified in the
preoperative setting, rather than treatment- or
postoperative-related variables. In this way, the score can
help identify patients who might benefit from consider-
ation of other therapeutic approaches, including preopera-
tive chemotherapy. Indeed, our group previously reported
that a subset of patients with ICC can benefit from the use
of preoperative chemotherapy.2
The current study had several limitations. Although
data from multiple institutions increased the sample
size, some degree of heterogeneity in terms of diagnostic,
treatment, and follow-up protocols among the partici-
pating institutions was likely. Nonetheless, the use of an
international, multi-institutional study design provided
greater statistical power and increased the generalizability
of the results. Although the preoperative score wasassessed using an internal test dataset, external validation
will be required, particularly in cohorts that might have
been under-represented in the current study.CONCLUSIONS
The current study defined and validated a preoperatively
assessable, continuous risk score for patients with surgi-
cally resectable ICC. Importantly, the proposed score
not only accounted for a variety of factors, such as tumor
morphology, tumor biology, liver function, and host-
tumor interactions, but also outperformed the AJCC 8th
edition staging system for ICC. In turn, the preoperative
risk model can be used to inform preoperative consulta-
tions and guide the design of future studies aimed to
determine the most appropriate treatment for patients
with different risk profiles.Author Contributions
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J Gastrointest Surg 2014;18:1284e1291.DiscussionDR CHARLES SCOGGINS (Louisville, KY): This paper is an
example of the quality work that can be done when good surgeons
gather their data together and collaborate for the common good.
This model uses factors available in the preoperative setting.
Although I can appreciate that it is moderately predictive and seemsto provide valuable prognostic information, you did demonstrate
that it is associated with pathologic markers that are more
commonly used for predicting survival. Why not expand your
model and include factors such as nodal status and margin status?
It might enhance the model and make it even more predictive.
Many have sought to implicate systemic inflammation in a vari-
ety of diseases, including just about every cancer you can think of.
You used a common surrogate for inflammationdthe neutrophil-
to-lymphocyte ratio. In your multivariate model, the hazard ratio
for this factor was only 1.05, indicating a 5% higher risk. Do
you think this is the best marker for inflammation? What happens
to your predictive model if you leave it out?
Finally, how would you use this scoring system clinically? If you
have a preoperative patient with a poor score, would you offer him
or her another form of therapy? Systemic chemotherapy combined
with drug-eluting bead chemoembolization might have a similar
survival for such patients. Would you deny a resectable patient a
resection based on your score?
DR MARIA B MAJELLA DOYLE (St Louis, MO): As we have
heard, the authors are presenting work from an outstanding
multi-institutional collaboration between 16 international centers,
on outcomes after resection for intrahepatic cholangiocarcinoma
(ICC) in more than 500 patients. Based on their results, the authors
have created and validated a preoperative scoring system as a tool to
predict prognosis after resection using preoperatively available clin-
ical parameters.
First, what was the role was of neoadjuvant therapy for the study
patients? Does neoadjuvant therapy affect the usefulness of the
score? Additionally, if patients receive neoadjuvant therapy, can
they improve their score or prognosis after they have had neoadju-
vant therapy?
Second, can you comment on recurrence-free survival, which is
not provided in the current manuscript? It seems to me that this
would be a critically important factor in prognosticating cancer-
specific survival.
Finally, the role of liver transplantation for early hepatocellular
carcinoma and for selective hilar cholangiocarcinoma patients is
well established. What do you think is the role of liver transplanta-
tion in ICC? There have been some studies looking at transplanta-
tion for early ICC with excellent results. Were any of the patients in
the study considered for liver transplantation for their early ICC?
DR LEONIDAS KONIARIS (Indianapolis, IN): Did all of the insti-
tutions do lymphadenectomy for the ICCs? If they did, why do you
think lymph nodes did not seem to make a difference? If lymph
nodes do not make a difference, do you need to perform a lympha-
denectomy for ICC?
DR CLIFFORD KO (Los Angeles, CA): I wanted to get your
opinion on the types of data we would use for a prognostic model.
When we made the NSQIP Risk Calculator, we had all kinds of
variables that we thought were important for patient comorbidities.
In a cancer situation with the American Joint Committee on Can-
cer, we are going on cancer information with intermediate
